Abstract is: Malcolm K. Brenner (born August 4, 1951, in the UK) is a British clinical scientist working mostly in the field of gene therapy and immunotherapy applied to malignancy. In 2016, Dr. Brenner was elected to the National Academy of Medicine, part of the National Academies of Sciences, Engineering, and Medicine. He was educated at Forest School, Walthamstow and Emmanuel College, Cambridge England. He received his medical degree and subsequent Ph.D. from Cambridge University, England. In the 1980s, he was a Lecturer in Hematology at Royal Free Hospital in London. In 1990, he left the UK to work in St. Jude Children's Research Hospital in Memphis as the director of the Bone Marrow Transplant Division. There, he conducted one of the first human gene therapy studies when he transduced bone marrow stem cells with a with the intention of marking them to study their survival and fate. This seminal study demonstrated that engrafted bone marrow stem cells contribute to long-term hematopoiesis and also that contaminating tumor cells in autografts can cause relapse. In 1994, he became the director of St. Jude's Cell and Gene Therapy Program. The move in 1994 reflected his growing interest in the genetic-modification of T-cells for cancer therapy, cancer vaccines and monoclonal antibodies. He was President of the International Society for Cellular Therapy and President of the American Society of Gene Therapy in 2002–2003. He was appointed Editor in Chief of the journal Molecular Therapy in 2009. Dr. Brenner was appointed Director of the Center for Cell and Gene Therapy. Dr. Brenner's is a full-time faculty member for the Center for Cell and Gene Therapy, Texas Children's Cancer Center and the Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas. In 2017, Dr. Brenner was awarded the European Society of Gene and Cell Therapy Outstanding Achievement Award, and in 2020 the Career Achievement Award in Cell & Gene Therapy from the .
| human | Q5 |
| P646 | Freebase ID | /m/07bvjx |
| P7502 | Golden ID | Malcolm_Brenner-VKGAJP |
| P496 | ORCID iD | 0000-0002-3657-7675 |
| P3368 | Prabook ID | 2257430 |
| P27 | country of citizenship | United Kingdom | Q145 |
| P69 | educated at | Emmanuel College | Q797892 |
| Forest School | Q5469106 | ||
| P734 | family name | Brenner | Q909257 |
| Brenner | Q909257 | ||
| Brenner | Q909257 | ||
| P735 | given name | Malcolm | Q6584302 |
| Malcolm | Q6584302 | ||
| P1412 | languages spoken, written or signed | English | Q1860 |
| P106 | occupation | researcher | Q1650915 |
| immunologist | Q12119633 | ||
| P21 | sex or gender | male | Q6581097 |
| Q28553703 | 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one |
| Q38798085 | 3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirus |
| Q90878344 | A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia |
| Q34044757 | A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy |
| Q35976599 | A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies |
| Q40404804 | A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells |
| Q40775499 | A comparison of double beta-lactam combinations with netilmicin/ureidopenicillin regimens in the empirical therapy of febrile neutropenic patients |
| Q45880611 | A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy |
| Q24564100 | A distinct "side population" of cells with high drug efflux capacity in human tumor cells |
| Q33182313 | A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia |
| Q44431926 | A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells |
| Q82195538 | A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma |
| Q36467473 | A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease |
| Q42557864 | A question of reproducibility |
| Q40605843 | A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells |
| Q34273968 | Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. |
| Q45885336 | Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. |
| Q36209019 | Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation |
| Q45862006 | Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells |
| Q40787404 | Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. |
| Q45736315 | Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma |
| Q41925180 | Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer |
| Q45419330 | Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma |
| Q41034862 | Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. |
| Q40866408 | Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease |
| Q41484650 | Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts |
| Q92337111 | Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia |
| Q92234074 | Adoptive Cell Therapy: ACT-Up or ACT-Out? |
| Q34977470 | Adoptive T cell therapy of cancer |
| Q37268297 | Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia |
| Q40924104 | Adoptive immunotherapy for Epstein-Barr virus-related lymphoma |
| Q34302502 | Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines |
| Q42007990 | Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation |
| Q34242449 | Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma |
| Q46561276 | Adoptive transfer of rapidly-generated multivirus-specific T cells to treat Adv, EBV, CMV, BK and HHV6 infections of HSCT recipients |
| Q34039992 | Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience |
| Q40406380 | Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection |
| Q70232407 | Allogeneic bone marrow transplantation. Recent developments and the potential expansion of the donor pool |
| Q90067455 | Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients |
| Q34374139 | Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects |
| Q40695082 | Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity |
| Q35195407 | American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells |
| Q40830952 | An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs |
| Q34044130 | An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells |
| Q67848511 | An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer |
| Q33196143 | An in vivo propagated human acute myeloid leukemia expressing ABCA3. |
| Q41768001 | An inducible caspase 9 safety switch for T-cell therapy |
| Q42622440 | An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies |
| Q70385058 | Analysis of signal transduction in B chronic lymphocytic leukemia cells |
| Q97677126 | Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma |
| Q45856415 | Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation |
| Q70557646 | Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors |
| Q35693709 | Antigen-induced regulatory T cells |
| Q35604043 | Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma |
| Q39984618 | Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor |
| Q45884456 | Antitumor responses induced by transgenic expression of CD40 ligand |
| Q27028006 | Antiviral T-cell therapy |
| Q38714964 | Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors |
| Q43236749 | Assessing journal influence: impacted wisdom |
| Q45858310 | Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. |
| Q72103186 | Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission |
| Q77899763 | Autoimmune disease induced by dendritic cell immunization against leukemia |
| Q40572376 | Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection |
| Q45878196 | Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes |
| Q61909074 | Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia |
| Q52131763 | B cell development and regulation after T cell-depleted marrow transplantation. |
| Q74165624 | BMT beats autoimmune disease |
| Q45883748 | Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses |
| Q69912465 | Bioactivity and immunoreactivity of tumour necrosis factor in cancer patients |
| Q45879359 | Bone marrow transplant recipients have defective MHC-unrestricted cytotoxic responses against cytomegalovirus in comparison with Epstein-Barr virus: the importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1) |
| Q54378659 | Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. |
| Q43516881 | Bone marrow transplantation in acute or chronic leukaemia |
| Q34576976 | Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity |
| Q40704944 | Bronchiolitis obliterans organizing pneumonia (BOOP) in children after allogeneic bone marrow transplantation |
| Q40651719 | Bystander Transfer of Functional Human CD40 Ligand from Gene-Modified Fibroblasts to B-Chronic Lymphocytic Leukemia Cells |
| Q45873673 | C-MPL provides tumor-targeted T cell receptor-transgenic T cells with co-stimulation and cytokine signals |
| Q45868734 | CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma |
| Q55382852 | CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. |
| Q37316892 | CAR T cells for acute myeloid leukemia: the LeY of the land |
| Q36519358 | CAR-T Cell Therapy for Lymphoma. |
| Q45744642 | CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation |
| Q34876434 | CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients |
| Q45883456 | CD40 ligand induces an antileukemia immune response in vivo. |
| Q40259994 | CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. |
| Q68187913 | CD5-positive B cells after T cell depleted bone marrow transplantation |
| Q43745893 | CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors |
| Q58584621 | CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia |
| Q38702393 | CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. |
| Q68238839 | CMV-induced augmentation of GVL effect may be mediated by cytokines |
| Q77057632 | Cancer vaccines |
| Q35015194 | Cancer vaccines: dream, reality, or nightmare? |
| Q30452811 | Cell-specific transmembrane injection of molecular cargo with gold nanoparticle-generated transient plasmonic nanobubbles |
| Q33186636 | Cells of the hepatic side population contribute to liver regeneration and can be replenished with bone marrow stem cells. |
| Q84669662 | Cellular Immunotherapy of Cancer |
| Q37387518 | Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics |
| Q48034648 | Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis |
| Q45865254 | Children with acute leukemia: A comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation |
| Q64062556 | Chimeric Antigen Receptors for T-Cell Malignancies |
| Q35570309 | Chimeric T-Cell Receptors for the Targeting of Cancer Cells |
| Q42412764 | Clinical Success of Complex Biological Therapies: Be Careful What You Wish For.. |
| Q40084076 | Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes |
| Q104059773 | Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant |
| Q37042225 | Clinical responses with T lymphocytes targeting malignancy-associated κ light chains |
| Q41071748 | Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch |
| Q36059585 | Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. |
| Q71607043 | Combined chemokine and cytokine gene transfer enhances antitumor immunity |
| Q37443603 | Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer |
| Q45880993 | Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen |
| Q45864372 | Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia |
| Q40463236 | Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. |
| Q36941738 | Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia |
| Q45862820 | Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. |
| Q36059593 | Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer |
| Q44987334 | Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells |
| Q45871070 | Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. |
| Q33493622 | Continuous infusion of interleukin-2 in children with refractory malignancies |
| Q72229261 | Correction of Duncan's syndrome by allogeneic bone marrow transplantation |
| Q54254166 | Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. |
| Q38624844 | Current role and status of bone marrow transplantation |
| Q64891207 | Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital |
| Q54377678 | Cytokine-induced enhancement of the susceptibility of hairy cell leukaemia lymphocytes to natural killer cell lysis. |
| Q45773204 | Cytologic diagnosis of respiratory syncytial virus infection in a bronchoalveolar lavage specimen from a bone marrow transplant recipient |
| Q46693840 | Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab |
| Q69903373 | Cytomegalovirus pneumonitis after allogeneic marrow transplantation |
| Q36399791 | Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease |
| Q37414729 | Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation |
| Q34018782 | Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma |
| Q41149412 | Cytotoxic effects of tumour necrosis factor and gamma-interferon on acute myeloid leukaemia blasts |
| Q47682895 | Delayed Induction of Proto-Oncogene Expression in B-CLL Cells by Tumor Necrosis Factor |
| Q33780277 | Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation |
| Q37418289 | Design and development of therapies using chimeric antigen receptor-expressing T cells |
| Q37204216 | Developing T-cell therapies for cancer in an academic setting |
| Q69021535 | Differential expression of MHC class II antigens in chronic B-cell disorders |
| Q70056223 | Differential recovery of phenotypically and functionally distinct circulating antigen-presenting cells after allogeneic marrow transplantation |
| Q54199437 | Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. |
| Q35326940 | Do double-beta-lactam combinations prolong neutropenia in patients undergoing chemotherapy or bone marrow transplantation for hematological disease? |
| Q72110900 | Donor T cells to treat EBV-associated lymphoma |
| Q64379383 | E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells |
| Q45888825 | EBV specific CTL: a model for immune therapy |
| Q59351745 | EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation |
| Q45784379 | Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease |
| Q35136456 | Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application |
| Q67540536 | Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia |
| Q36354141 | Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders |
| Q69775471 | Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy |
| Q68102021 | Effects of tumour necrosis factor and alpha interferon on chronic B cell malignancies |
| Q37559470 | Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. |
| Q33182157 | Efficient infection of primitive hematopoietic stem cells by modified adenovirus |
| Q69186500 | Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy |
| Q33578792 | Engineered T cells for cancer treatment |
| Q97531713 | Engineered off-the-shelf therapeutic T cells resist host immune rejection |
| Q41179125 | Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety |
| Q40019570 | Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment |
| Q39655872 | Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. |
| Q69564898 | Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF |
| Q89030540 | Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment |
| Q37129671 | Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients |
| Q36007685 | Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease |
| Q40757918 | Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas |
| Q45756934 | Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease |
| Q45733496 | Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy |
| Q34550028 | Evaluation of test immunisation in the assessment of antibody deficiency syndromes |
| Q36399240 | Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes |
| Q45874973 | Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease |
| Q64377545 | Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15 |
| Q37098062 | Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy |
| Q45723104 | Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect |
| Q54377671 | Expression of tartrate-resistant acid phosphatase in B-CLL treated with phorbol ester or phorbol ester plus calcium ionophore. |
| Q44469847 | Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remission |
| Q69495288 | Fatal hepatitis B reactivation after autologous bone marrow transplantation |
| Q40629249 | Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications |
| Q37585288 | Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". |
| Q42967415 | Fine-tuning the CAR spacer improves T-cell potency |
| Q33372388 | Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences |
| Q37334642 | Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes |
| Q38782845 | GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade |
| Q71100864 | Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors |
| Q68475233 | Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus |
| Q24792778 | Gene Therapy for Pediatric Cancer: State of the Art and Future Perspectives |
| Q45888812 | Gene and cell transfer for specific immunotherapy |
| Q40470692 | Gene marking after bone marrow transplantation. |
| Q40667892 | Gene marking and autologous bone marrow transplantation |
| Q41236567 | Gene marking and gene therapy for transplantation medicine |
| Q72656870 | Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients |
| Q72706982 | Gene marking to improve the outcome of autologous bone marrow transplantation |
| Q71809756 | Gene transfer and bone marrow transplantation |
| Q40537211 | Gene transfer into human hemopoietic progenitor cells |
| Q33911434 | Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease |
| Q41137652 | Gene-marking and haemopoietic stem-cell transplantation |
| Q34261323 | Gene-marking studies of hematopoietic cells |
| Q49158499 | Gene-marking to trace origin of relapse after autologous bone-marrow transplantation |
| Q38230157 | Gene-modified cells for stem cell transplantation and cancer therapy |
| Q40758939 | Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals |
| Q37450543 | Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506) |
| Q40777664 | Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients |
| Q64375195 | Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma |
| Q39506626 | Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. |
| Q34644876 | Genetic modification of T cells |
| Q35826514 | Genetic modification of T lymphocytes for adoptive immunotherapy |
| Q45907207 | Go-CART: an animal-free system for the assessment of CAR T cell function. |
| Q68882650 | Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation |
| Q37545989 | Graft versus leukaemia effects after marrow transplantation in man. |
| Q44894428 | Graft-versus-host reactions and bone-marrow transplantation |
| Q40234446 | HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial |
| Q35859432 | Haematopoietic stem cell transplantation for autoimmune disease: limits and future potential |
| Q68904722 | Haemolysis after T-cell depleted bone marrow transplantation involving minor AB0 incompatibility |
| Q43281253 | Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study |
| Q70404592 | Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy |
| Q73329414 | Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy |
| Q40035096 | Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis |
| Q52598637 | High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. |
| Q33806895 | High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells |
| Q64382811 | High-efficiency transduction of freshly isolated human tumor cells using adenoviral interleukin-2 vectors |
| Q37919880 | Highlights of the second international conference on "Immunotherapy in Pediatric Oncology". |
| Q67984532 | Homeostatic action of interleukin-4 on endogenous and recombinant interleukin-2-induced activated killer cell function |
| Q70990133 | Human B cell growth factors overcome T cell-mediated inhibition of specific antibody production: a possible mechanism for the exacerbation of autoimmune disease |
| Q35598804 | Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma |
| Q40457809 | Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. |
| Q71670230 | Human gene marker/therapy clinical protocols |
| Q71855601 | Human gene marker/therapy clinical protocols |
| Q73299269 | Human gene marker/therapy clinical protocols |
| Q73707811 | Human gene marker/therapy clinical protocols |
| Q74116254 | Human gene marker/therapy clinical protocols |
| Q45867015 | Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation |
| Q68934887 | Human large granular lymphocytes induce immunoglobulin synthesis after bone marrow transplantation |
| Q34501316 | Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. |
| Q42853387 | Hypoxic adipocytes pattern early heterotopic bone formation. |
| Q64381962 | IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma |
| Q52077808 | IL-2 infusion abrogates humoral immune responses in humans. |
| Q43743694 | IL-4 acts as a homeostatic regulator of IL-2-induced TNF and IFN-gamma |
| Q41129529 | IL2 activated killer cells may contribute to cytomegalovirus induced marrow hypoplasia after bone marrow transplantation |
| Q35156105 | IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity |
| Q45857428 | Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. |
| Q33303005 | Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy |
| Q69896628 | Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections |
| Q35020998 | Immune therapy for EBV infections after hemopoietic stem-cell transplant |
| Q43496476 | Immunity against Pseudomonas aeruginosa adoptively transferred to bone marrow transplant recipients |
| Q71939023 | Immunomodulatory effects of human neuroblastoma cells transduced with a retroviral vector encoding interleukin-2 |
| Q37006823 | Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation |
| Q38778924 | Immunotherapy against cancer-related viruses |
| Q45754212 | Immunotherapy for Epstein-Barr virus-associated cancers |
| Q40603025 | Immunotherapy for Hodgkin's disease. |
| Q35848688 | Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. |
| Q34188383 | Immunotherapy of human cancers using gene modified T lymphocytes |
| Q35920692 | Immunotherapy of leukemia |
| Q42557896 | Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells |
| Q38719148 | Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer |
| Q38912826 | Improving the safety of T-Cell therapies using an inducible caspase-9 gene |
| Q35681332 | In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia |
| Q57493527 | In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas |
| Q68134250 | In vitro analysis of the interactions of recombinant IL-2 with regenerating lymphoid and myeloid cells after allogeneic marrow transplantation |
| Q69224162 | In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation |
| Q47989777 | Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells |
| Q29617710 | Inducible apoptosis as a safety switch for adoptive cell therapy |
| Q41953436 | Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation |
| Q35784529 | Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation |
| Q39997530 | Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes |
| Q45754081 | Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. |
| Q37263151 | Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study |
| Q36361141 | Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia |
| Q36956269 | Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma |
| Q68210259 | Interleukin 2 enhances cytotoxic cell function in vitro after T-cell depleted marrow transplantation |
| Q70117776 | Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation |
| Q41028935 | Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma |
| Q68186088 | Interleukin-2 infusion after autologous bone marrow transplantation enhances hemopoietic regeneration |
| Q39085608 | Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition |
| Q41867400 | Intravenous gammaglobulin treatment in patients with hypogammaglobulinaemia. |
| Q42649858 | Introducing Molecular Therapy-Oncolytics |
| Q42334216 | Introducing a new ASGCT forum for publication of methodology and clinical development in gene, cell, and oligonucleotide therapies |
| Q42745908 | Introducing eJP. |
| Q43133831 | Introducing molecular therapy--methods & clinical development |
| Q37564361 | Is cancer gene therapy an empty suit? |
| Q67938701 | Is circulating tumor necrosis factor bioactive? |
| Q73635243 | Is retroviral gene marking too dangerous to use? |
| Q39064900 | Kinetics of tumor destruction by chimeric antigen receptor-modified T cells |
| Q73523478 | Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy |
| Q40565614 | Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids |
| Q40693626 | Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma |
| Q33781162 | Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene |
| Q33634455 | Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients |
| Q45771097 | Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes |
| Q41727048 | Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma |
| Q41782234 | Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication |
| Q36757082 | Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. |
| Q42736839 | Midlife moments |
| Q77678741 | Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma |
| Q45766725 | Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults |
| Q99556750 | Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia |
| Q45346828 | Molecular analysis of retroviral transduction in chronic myelogenous leukemia |
| Q45145816 | Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes |
| Q45862722 | Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals |
| Q37677563 | Mouse models in bone marrow transplantation and adoptive cellular therapy |
| Q36962653 | Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation |
| Q28828176 | Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch |
| Q45007248 | Natural killer cell activity following T-cell depleted allogeneic bone marrow transplantation |
| Q45864643 | Neuropathic dermatomes and cutaneous ulceration in patients with chronic GVHD. |
| Q45872300 | Next Steps in the CAR Journey of a Thousand Miles |
| Q71004514 | Non-specific factor enhancement of human in vitro antigen-dependent antibody synthesis: role of B cell activation and T cell help |
| Q33713932 | Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. |
| Q40092234 | Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation |
| Q90127107 | Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors |
| Q88681206 | Onward and upward for immuno-oncology |
| Q35813115 | Options for T-cell based therapies |
| Q35981394 | Origin of marrow stromal cells and haemopoietic chimaerism following bone marrow transplantation determined by in situ hybridisation |
| Q42433067 | Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution |
| Q82488232 | Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML) |
| Q45875334 | Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome |
| Q41234716 | Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies |
| Q73699531 | Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia |
| Q45863413 | Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells |
| Q37653325 | Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells |
| Q42689675 | Personalized medicine: words that mean just what you choose? |
| Q45280604 | Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector |
| Q40138863 | Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin |
| Q37422328 | Possible mechanism of action of interferon alpha in chronic B-cell malignancies |
| Q34792780 | Primitive adult hematopoietic stem cells can function as osteoblast precursors |
| Q42029211 | Production of anti-cytomegalovirus antibody following T-cell depleted bone marrow transplant |
| Q71004703 | Production of antibody by human B cells under serum-free conditions |
| Q41355210 | Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease |
| Q72580347 | Production of leucocyte interferon in vitro in children with recurrent respiratory infections |
| Q36994170 | Progress and prospects: gene therapy clinical trials (part 2). |
| Q44556923 | Prolonged remission of Epstein-Barr virus associated lymphoma secondary to T cell-depleted bone marrow transplantation |
| Q75365320 | Prompt versus preemptive intervention for EBV lymphoproliferative disease |
| Q71793103 | Psychological effects of bone marrow transplantation on children and adolescents: preliminary report of a longitudinal study |
| Q41260775 | Rapid expression of protooncogenes c-fos and c-myc in B-chronic lymphocytic leukemia cells during differentiation induced by phorbol ester and calcium ionophore |
| Q70039604 | Rapid recovery of helper activity following T cell depleted allogeneic marrow transplant |
| Q36142490 | Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections |
| Q78225285 | Reconstitution of early lymphoid proliferation and immune function in Jak3-deficient mice by interleukin-3 |
| Q67997641 | Reconstitution of the T cell receptor alpha beta repertoire in recipients of allogeneic BMT |
| Q68900059 | Recovery of immunoglobulin isotypes following T-cell depleted allogeneic bone marrow transplantation |
| Q45842346 | Regeneration of humoral immunity to herpes simplex virus following T-cell-depleted allogeneic bone marrow transplantation |
| Q43670392 | Requirements for the adoptive transfer of antibody responses to a priming antigen in man. |
| Q40972063 | Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1 |
| Q40366049 | Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia |
| Q54273250 | Retrovirus-mediated gene transfer as an approach to analyze neuroblastoma relapse after autologous bone marrow transplantation. |
| Q30580134 | Reversal of tumor immune inhibition using a chimeric cytokine receptor |
| Q45873677 | Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-Cell Malignancies. |
| Q37316838 | Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant |
| Q49608232 | Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy |
| Q33193068 | Selection of chronic lymphocytic leukemia binding peptides |
| Q30975728 | Selection of human antitumor single-chain Fv antibodies from the B-cell repertoire of patients immunized against autologous neuroblastoma |
| Q42678254 | Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression |
| Q40645495 | Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses |
| Q33718767 | Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine |
| Q40167916 | Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation |
| Q99407458 | Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4+ T cells |
| Q69218583 | Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy |
| Q68900066 | Standardization of T-cell depletion in HLA matched bone marrow transplantation |
| Q42852853 | Stemming our irrational exuberance |
| Q70801531 | Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors |
| Q45880996 | Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine |
| Q35068768 | Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins |
| Q70362248 | Synergistic action of calcium ionophore A23187 and phorbol ester TPA on B-chronic lymphocytic leukemia cells |
| Q33724261 | Systemic inflammatory response syndrome after administration of unmodified T lymphocytes |
| Q38624746 | T cell depleted bone marrow transplantation in acute myeloblastic leukaemia: the way ahead. |
| Q81155123 | T cell therapies |
| Q70139871 | T lymphocyte regeneration after transplantation of T cell depleted allogeneic bone marrow |
| Q37262424 | T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. |
| Q35848840 | T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells |
| Q90315321 | T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells |
| Q68927629 | T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2 |
| Q36953077 | T-cell therapy after hematopoietic stem cell transplantation |
| Q72923465 | TNF and chronic B lymphoproliferative disorders |
| Q37137932 | Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape |
| Q91546261 | Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape |
| Q40338282 | Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors |
| Q40552241 | Targeted delivery of adenoviral vectors by cytotoxic T cells |
| Q44954934 | Targeting CD19 with genetically modified EBV-specific human T lymphocytes |
| Q45881040 | Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes |
| Q37251673 | The clone ranger? |
| Q36735379 | The continuing contribution of gene marking to cell and gene therapy. |
| Q70303982 | The contribution of large granular lymphocytes to B cell activation and differentiation after T-cell-depleted allogeneic bone marrow transplantation |
| Q34057955 | The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia |
| Q31088065 | The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease |
| Q39148534 | The immunogenicity of virus-derived 2A sequences in immunocompetent individuals |
| Q70995653 | The interaction of specific T-cell help and non-specific B-cell growth factors in the production of anti-tetanus antibody by human B cells grown in serum-free microcultures |
| Q70506483 | The role of B cell differentiation factors and specific T cell help in the pathogenesis of primary hypogammaglobulinemia |
| Q98164177 | The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma |
| Q39748877 | The use of monoclonal antibodies in graft versus host disease prevention |
| Q44937387 | Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice |
| Q72832665 | Thymoma and hypogammaglobulinaemia with and without T suppressor cells |
| Q41244791 | Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster |
| Q42379534 | Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent |
| Q45858704 | Transduction of CD34(+) and CD34(-)/lin(-) hemopoietic progenitors by lentivirus vectors |
| Q45869940 | Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system |
| Q55241939 | Transfection and gene expression in normal and malignant primary B lymphocytes. |
| Q33762569 | Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant |
| Q44821334 | Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow |
| Q41523249 | Transfer of humoral immunity against cytomegalovirus proteins following transplantation of T-cell-depleted allogeneic bone marrow from seropositive donors |
| Q41652457 | Transfer of marker genes into hemopoietic progenitor cells. |
| Q34433292 | Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy |
| Q101225460 | Transgenic CD8αβ co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells |
| Q45887028 | Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells |
| Q45878878 | Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma |
| Q44927325 | Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation |
| Q40135347 | Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. |
| Q45551744 | Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes |
| Q40826462 | Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells |
| Q35849039 | Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs) |
| Q35757397 | Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs |
| Q69386265 | Tumor necrosis factor mediates autocrine growth inhibition in a chronic leukemia |
| Q97568608 | Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma |
| Q47218634 | Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma |
| Q69917734 | Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies |
| Q37707135 | Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. |
| Q45223159 | Unrelated donor marrow transplantation between 1977 and 1987 at four centers in the United Kingdom. |
| Q71624183 | Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation |
| Q71254319 | Use of gene marking in bone marrow transplantation |
| Q44618759 | Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation |
| Q36273626 | Vaccine therapies for pediatric malignancies |
| Q29622835 | Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma |
| Q42557804 | Where is the good in goodbye? |
| Q28286553 | XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors |
| Q53927291 | [Gene therapy of childhood cancers: current status and perspectives]. |
| Q61909145 | [Therapeutic advances in bone marrow transplantation] |
| Q36994717 | iCaspase 9 Suicide Gene System |
| Category:Malcolm Brenner | wikimedia | |
| Arabic (ar / Q13955) | مالكوم برينر | wikipedia |
| Malcolm Brenner | wikipedia | |
| Malcolm Brenner | wikipedia |
Search more.